A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

Summary

This study will evaluate the efficacy, safety, and tolerability of two doses of rapastinel, 225 milligrams (mg) and 450 mg, compared to placebo adjunctive to antidepressant therapy (ADT) in patients with major depressive disorder (MDD) who have a partial response to ADT.

Timeline

Start

2016-11-01

Primary completion

2018-12-12

Completion

2018-12-18

Drugs

Indications